Milestone Pharmaceuticals Inc (NASDAQ:MIST) does about 2.53M shares in volume on a normal day but saw 1792421 shares change hands in the recent trading day. The company now has a market cap of 75.91M USD. Its current market price is $1.42, marking a decrease of -7.79% compared to the previous close of $1.54. The 52 week high reached by this stock is $2.75 whilst the lowest price level in 52 weeks is $0.63. The script in recent trading has seen the stock touch a high of $10 and a low of $10.
3 analysts observing the Milestone Pharmaceuticals Inc (MIST) stock have set the 12-month price targets for the company’s shares at between $10 and $10. The consensus objective for the share price is $6.00, suggesting that the stock has a potential upside of 76.33% over the period. The median price target is 85.8% away from the current levels at $10.
FactSet Research has provided data showing that 3 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 3 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 22, 2024 when Rodman & Renshaw initiated the stock to “Buy” and issued a price target of $9. Jefferies downgraded the stock to “Hold” from Buy on June 20, 2023 at a price target of $8-$4. Piper Sandler upgraded its price target at $8-$10.
The current price level is 10.38%, 12.15%, and -12.88% away from its SMA20, SMA50, and SMA200 respectively, with the MIST price moving below the 50-day SMA on current market day. Milestone Pharmaceuticals Inc (MIST) stock is up 10.08% over the week and 10.94% over the past month. Its price is -39.83% year-to-date and -18.86% over the past year.
Its 12-month price target is $10. To reach the target analysts have set, the stock logically needs to grow 76.33 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $10, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $10.
Outstanding shares total 53.46M with insiders holding 4.71% of the shares and institutional holders owning 22.28% of the company’s common stock. The company has a return on investment of -106.14% and return on equity of -307.27%. The beta has a value of 0.89.
